CVR: 33161395
Secondary names: Specific Care A/S
SPECIFIC PHARMA A/S is a Danish company of the type Aktieselskab based in København SV, founded in 2010. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Uffe Kåre Jensen. The company is owned by NOMECO A/S. The company has 24 employees. In 2026, the company reported revenue of DKK 157,797,000 and a net result of DKK 15,192,000 compared with DKK 29,239,000 the year before. Equity amounted to DKK 98,645,000.
The financial health of SPECIFIC PHARMA A/S appears robust, with a notable upward trajectory in both revenue and profit over the past few years. Revenue increased from 123.3 million DKK in 2022 to 219.3 million DKK in 2025, while profit rose significantly from 7.8 million DKK to 29.2 million DKK in the same period, indicating strong operational efficiency and market demand. The company's equity has also improved, reaching 111.2 million DKK, which reflects a solid capital position. However, the fluctuating profit margins and lack of a CDS score may raise concerns regarding financial stability. Overall, SPECIFIC PHARMA A/S is well-positioned within the pharmaceutical wholesale industry, demonstrating growth potential and increasing profitability.
AI-generated summary
Your company? Claim the profile and show your logo, website and social channels — for free.
Claim this profileSelskabets formål er - direkte eller via besiddelse af kapitalandele i andre selskaber - at drive handel med og tilbyde serviceydelser inden for sundhedsområdet samt anden virksomhed, der efter bestyrelsens skøn er forbundet dermed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2026 | 157.8 mio. | 15.2 mio. | 115.2 mio. | 98.6 mio. | 33 | |
| 2025 | 219.3 mio. | 29.2 mio. | 134.5 mio. | 111.2 mio. | 28 | |
| 2024 | 211 mio. | 25.6 mio. | 126.2 mio. | 106.2 mio. | 25 | |
| 2023 | 177.6 mio. | 9.9 mio. | 105 mio. | 89.6 mio. | 25 | |
| 2022 | 123.3 mio. | 7.8 mio. | 103.1 mio. | 85.5 mio. | 23 | |
| 2021 | 139.6 mio. | 14.8 mio. | 107.2 mio. | 88.8 mio. | 21 | |
| 2020 | 128.2 mio. | 8.2 mio. | 95.3 mio. | 80.2 mio. | 16 | |
| 2019 | 146.4 mio. | 8.9 mio. | 93.1 mio. | 78.6 mio. | 15 | |
| 2018 | 145.7 mio. | 14.8 mio. | 87.4 mio. | 69.7 mio. | 12 | |
| 2017 | 142.4 mio. | 26.2 mio. | 100.2 mio. | 74.6 mio. | 8 | |
| 2016 | 141.1 mio. | 20.2 mio. | 82.6 mio. | 63.5 mio. | 8 | |
| 2015 | 132 mio. | 24.1 mio. | 96.8 mio. | 61.4 mio. | 4 | |
| 2014 | 137.8 mio. | 18.7 mio. | 52.5 mio. | 37.3 mio. | - | |
| 2013 | 60.1 mio. | 10.6 mio. | 24.5 mio. | 18.6 mio. | - |
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationCompared to 412 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
1 public tender won
Sources: TED (the EU tender database) and udbud.dk
Screen owners and management against the Danish FSA's official PEP lists
SPECIFIC PHARMA A/S has published its annual report for 2026. Revenue came to DKK 157,797,000, and the net result was DKK 15,192,000.
Contact info changed: new email: [email protected] (June 23, 2026).
Contact info changed: new email: [email protected] (June 18, 2026).
Contact info changed: new email: [email protected] (June 17, 2026).
As of June 17, 2026, Kasper Casparij Yde has joined the board of directors of SPECIFIC PHARMA A/S.
As of June 17, 2026, Pia Rask Stewart has left the board of directors of SPECIFIC PHARMA A/S.
Contact info changed: new email: [email protected] (March 31, 2026).
As of March 23, 2026, Kristine Sakstrup Haag has joined the board of directors of SPECIFIC PHARMA A/S.
As of March 23, 2026, Henrik Kaastrup has joined the board of directors of SPECIFIC PHARMA A/S.
As of March 22, 2026, Kristine Sakstrup Haag has left the board of directors of SPECIFIC PHARMA A/S.
As of March 22, 2026, Henrik Kaastrup has left the board of directors of SPECIFIC PHARMA A/S.
SPECIFIC PHARMA A/S has won the tender "Udbudsnummer 1" issued by Amgros I/S worth 46,824,716 DKK.
SPECIFIC PHARMA A/S has published its annual report for 2025. Revenue came to DKK 219,329,000, and the net result was DKK 29,239,000.
As of June 26, 2025, Forvis Mazars Statsautoriseret Revisionspartnerselskab has been appointed auditor of SPECIFIC PHARMA A/S.
As of June 26, 2025, EY Godkendt Revisionspartnerselskab has stepped down as auditor of SPECIFIC PHARMA A/S.
SPECIFIC PHARMA A/S has published its annual report for 2024. Revenue came to DKK 210,987,000, and the net result was DKK 25,560,000.
As of October 6, 2023, Ole Markussen has left the board of directors of SPECIFIC PHARMA A/S.
SPECIFIC PHARMA A/S has published its annual report for 2023. Revenue came to DKK 177,609,000, and the net result was DKK 9,876,000.
SPECIFIC PHARMA A/S has published its annual report for 2022. Revenue came to DKK 123,270,000, and the net result was DKK 7,769,000.
SPECIFIC PHARMA A/S has published its annual report for 2021. Revenue came to DKK 139,630,000, and the net result was DKK 14,799,000.
As of December 4, 2020, Pia Rask Stewart has joined the board of directors of SPECIFIC PHARMA A/S.
As of December 4, 2020, Per Bornhøft Hansen has left the board of directors of SPECIFIC PHARMA A/S.
SPECIFIC PHARMA A/S has published its annual report for 2020. Revenue came to DKK 128,248,000, and the net result was DKK 8,237,000.
As of August 27, 2019, Ken Rasmussen has joined the board of directors of SPECIFIC PHARMA A/S.
SPECIFIC PHARMA A/S has published its annual report for 2019. Revenue came to DKK 146,427,000, and the net result was DKK 8,914,000.
As of June 13, 2019, Ole Markussen has joined the board of directors of SPECIFIC PHARMA A/S.
As of May 2, 2019, Ole Markussen has stepped down as adm. dir. of SPECIFIC PHARMA A/S.
As of May 1, 2019, Uffe Kåre Jensen is registered as adm. dir. of SPECIFIC PHARMA A/S.
As of January 3, 2019, Samia Sofie Kappe has stepped down as adm. dir. of SPECIFIC PHARMA A/S.
As of January 1, 2019, Ole Markussen is registered as adm. dir. of SPECIFIC PHARMA A/S.
SPECIFIC PHARMA A/S has published its annual report for 2018. Revenue came to DKK 145,726,000, and the net result was DKK 14,821,000.
SPECIFIC PHARMA A/S has published its annual report for 2017. Revenue came to DKK 142,444,000, and the net result was DKK 26,240,000.
SPECIFIC PHARMA A/S has published its annual report for 2016. Revenue came to DKK 141,067,000, and the net result was DKK 20,193,000.
SPECIFIC PHARMA A/S has published its annual report for 2015. Revenue came to DKK 132,005,000, and the net result was DKK 24,131,000.
As of November 1, 2014, Per Bornhøft Hansen has joined the board of directors of SPECIFIC PHARMA A/S.
As of November 1, 2014, Henrik Kaastrup has joined the board of directors of SPECIFIC PHARMA A/S.
As of November 1, 2014, Samia Sofie Kappe is registered as adm. dir. of SPECIFIC PHARMA A/S.
As of November 1, 2014, Henrik Kaastrup has stepped down as adm. dir. of SPECIFIC PHARMA A/S.
As of October 10, 2014, EY Godkendt Revisionspartnerselskab has been appointed auditor of SPECIFIC PHARMA A/S.
As of October 10, 2014, JUT NR. 2180 A/S has stepped down as auditor of SPECIFIC PHARMA A/S.
As of September 15, 2014, NOMECO A/S is registered as an owner of SPECIFIC PHARMA A/S with an ownership share of 100%.
As of July 4, 2014, Henrik Kaastrup is registered as adm. dir. of SPECIFIC PHARMA A/S.
As of June 29, 2014, Ulf Blangsted Henriksen has stepped down as adm. dir. of SPECIFIC PHARMA A/S.
SPECIFIC PHARMA A/S has published its annual report for 2014. Revenue came to DKK 137,766,000, and the net result was DKK 18,713,000.
As of April 28, 2014, Kristine Sakstrup Haag has joined the board of directors of SPECIFIC PHARMA A/S.
As of April 28, 2014, Søren Vesti Esbensen has joined the board of directors of SPECIFIC PHARMA A/S.
As of April 28, 2014, Søren Vesti Esbensen has left the board of directors of SPECIFIC PHARMA A/S.
SPECIFIC PHARMA A/S has published its annual report for 2013. Revenue came to DKK 60,116,598, and the net result was DKK 10,587,627.
As of June 25, 2012, JUT NR. 2180 A/S has been appointed auditor of SPECIFIC PHARMA A/S.
As of June 25, 2012, EY Danmark A/S has stepped down as auditor of SPECIFIC PHARMA A/S.
As of April 16, 2012, Søren Vesti Esbensen has joined the board of directors of SPECIFIC PHARMA A/S.
As of April 16, 2012, Jan Bonde has left the board of directors of SPECIFIC PHARMA A/S.
As of April 16, 2012, Tina Majgård Moltke-Leth has left the board of directors of SPECIFIC PHARMA A/S.
As of February 28, 2011, Tina Majgård Moltke-Leth has joined the board of directors of SPECIFIC PHARMA A/S.
As of February 28, 2011, Ole Markussen has left the board of directors of SPECIFIC PHARMA A/S.
As of September 15, 2010, EY Danmark A/S has been appointed auditor of SPECIFIC PHARMA A/S.
As of September 15, 2010, Jan Bonde has joined the board of directors of SPECIFIC PHARMA A/S.
As of September 15, 2010, Ole Markussen has joined the board of directors of SPECIFIC PHARMA A/S.
As of September 15, 2010, Ulf Blangsted Henriksen is registered as adm. dir. of SPECIFIC PHARMA A/S.
SPECIFIC PHARMA A/S was founded on September 15, 2010.
Companies in the same industry and area
CVR 43707795
CVR 33597037
CVR 40486585
CVR 33671245
CVR 40041796
companydata.dk